Determination of Irisin, Body Mass Index, and Other Biochemical Parameters in a Sample of Iraqi Type II Diabetic Patients

Takwa Al Koloob Ali  Chachan; Huda Farhan; Shatha Hamed

doi:10.51173/jt.v4i3.559

Authors

Takwa Al Koloob Ali Chachan College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Huda Farhan College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Shatha Hamed Laboratories Department, Medical Technology B.Sc. PG Dip, Iraqi Ministry of Health

DOI:

https://doi.org/10.51173/jt.v4i3.559

Keywords:

Irisin, T2DM, BMI, Lipid profile

Abstract

Evidence suggests that Irisin, a peptide hormone, may play a role in lipid metabolism, insulin resistance, and obesity. On the other hand, its role in type 2 diabetic Mellitus [T2DM] in humans is uncertain. As a result, we investigated if irisin levels in T2DM patients were dysregulated and whether there was a link between serum irisin levels and anthropometric obesity indices and biochemical parameters. [T2DM patients] group [n = 90] and control groups [n = 90], males [n=81], females [n=99] were selected among 180 people. [43.17 ±11.13] years was the average age. ELISA was used to measure serum irisin levels. The mean serum Irisin level in the control group was considerably higher [P<0.01] than in the case group [6.9±1.3 vs. 5.8±1.2], respectively. The results showed that body mass index and irisin [P-value<0.001]. Irisin seems to have a significant negative connection [P-value<0.001] with body mass index, fasting blood sugar, glycated hemoglobin, insulin, and homeostasis model assessment of insulin resistance. There was also a substantial negative association between irisin, low-density lipoprotein, and triglyceride, but none with cholesterol or high-density lipoprotein. In conclusion, irisin appears to be involved in regulating glucose metabolism. In this investigation, circulating irisin concentrations were considerably lower in T2DM patients. These findings imply that higher plasma irisin levels in T2DM are linked to adiposity indices. As a result, irisin has the potential to be a novel therapeutic option in the field of obesity.

Downloads

Download data is not yet available.

References

Abbas KM, Alaaraji SFT, Alâ RS. A study of the association between IL-17 and HOMA-IR in Iraqi type 2 diabetic patients. Iraqi J Sci. 2020;491–8.

Zheng Y, Ley SH, Hu FB. Global etiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14[2]:88–98.

Gastaldelli A, Cusi K, Landó LF, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes [SURPASS-3 MRI]: a substudy of the randomise, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10[6]:393–406.

Barbagallo M, Veronese N, Dominguez LJ. Magnesium in Type 2 Diabetes Mellitus, Obesity, and Metabolic Syndrome. Vol. 14, Nutrients. MDPI; 2022. p. 714.

Koo BK, Lim S. Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease. Clin Obes Adults Child. 2022;159–77.

Elizondo-Montemayor L, Gonzalez-Gil AM, Tamez-Rivera O, Toledo-Salinas C, Peschard-Franco M, Rodríguez-Gutiérrez NA, et al. Association between irisin, hs-CRP, and metabolic status in children and adolescents with type 2 diabetes mellitus. Mediators Inflamm. 2019.

Castillo-Quan JI. From white to brown fat through the PGC-1α-dependent myokine irisin: Implications for diabetes and obesity. DMM Dis Model Mech. 2012;5[3]:293–5.

Xia H, Scholtes C, Dufour CR, Ouellet C, Ghahremani M, Giguère V. Insulin action and resistance are dependent on a GSK3β-FBXW7-ERRα transcriptional axis. Nat Commun. 2022;13[1]:1–19.

Yardimci A, Ulker N, Bulmus O, Sahin E, Alver A, Gungor IH, et al. Irisin improves high-fat diet-induced sexual dysfunction in obese male rats. Neuroendocrinology. 2022;1–17.

Kopuz TNY, Dagdeviren M, Fisunoglu M. Serum irisin levels in newly diagnosed type-II diabetic patients: No association with the overall diet quality but a strong association with fruit intake. Clin Nutr ESPEN. 2022;49:357–64.

Bohórquez-Medina AL, Bohórquez-Medina SL, Benites-Zapata VA. Biological Markers of Insulin Sensitivity Links with Dietary Antioxidant. In: Biomarkers in Diabetes. Springer; 2022. p. 1–22.

Chawla R, Madhu S V, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for managing type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020;24[1]:1.

Al-Attaby AKT, Al-Lami MQD. Role of calcium-regulating hormones, adipocytokines, and renal function test in the progress of type 2 diabetes mellitus in a sample of Iraqi patients. Iraqi J Agric Sci. 2019;50[1]:343–51.

Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care. 2008;31[10]:1985–90.

Esser N, Utzschneider KM, Kahn SE. Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia. 2020;63[10]:2007–21.

De Tata V. Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol [Lausanne]. 2014;5:138.

Mansour AA, Al-Maliky AA, Kasem B, Jabar A, Mosbeh KA. Prevalence of diagnosed and undiagnosed diabetes mellitus in adults aged 19 years and older in Basrah, Iraq. Diabetes, Metab Syndr Obes Targets Ther. 2014;7:139.

Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology, and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37[3]:278–316.

Tonolo G. Sex-Gender Awareness in Diabetes. 2021;117–22.

Bitoska I, Krstevska B, Milenkovic T, Subeska-Stratrova S, Petrovski G, Mishevska SJ, et al. Effects of hormone replacement therapy on insulin resistance in postmenopausal diabetic women. Maced J Med Sci. 2016;4[1]:83–8.

Noor Kareem Abbas, Studying Reactive Oxygen SpeciesCopper, Zinc and Chromium in a Sample of type 2 Diabetic Patients, thesis Middle Technical UniversityCollege of Health & Medical Technology/Baghdad,2022

Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients. 2013;5[6]:2019–27.

Consitt L a, Newton C a, Collier DN, Dar MS, Tanner CJ. Page 1 of 40 Diabetes. Am J Hypertens. 2013;1–40.

Pérez-Sotelo D, Roca-Rivada A, Baamonde I, Baltar J, Castro AI, Domínguez E, et al. Lack of Adipocyte-Fndc5/Irisin Expression and Secretion Reduces Thermogenesis and Enhances Adipogenesis. Sci Rep. 2017;7[1]:1–15.

Bawady N, Aldafrawy O, ElZobair EM, Suliman W, Alzaabi A, Ahmed SH. Prevalence of Overweight and Obesity in Type 2 Diabetic Patients Visiting PHC in the Dubai Health Authority. Dubai Diabetes Endocrinol J. 2022;28[1]:20–4.

Damian DJ, Kimaro K, Mselle G, Kaaya R, Lyaruu I. Prevalence of overweight and obesity among type 2 diabetic patients attending diabetes clinics in northern Tanzania. BMC Res Notes. 2017;10[1]:1–6.

Kurir TT, Miličević T, Novak A, Vilović M, Božić J. Adropin - potential link in cardiovascular protection for obese male type 2 diabetes mellitus patients treated with liraglutide. Acta Clin Croat. 2020;59[2]:344–50.

Inaishi J, Saisho Y. Beta-cell mass in obesity and type 2 diabetes, and its relation to pancreas fat: A mini-review. Nutrients. 2020;12[12]:1–16.

Jawad AH, Al-Qaisi ZH, Ibrahim AE, Hallab ZS, Graisa A, 5 AA-A, et al. Effect of Anti Diabetic Drugs on Lipid Profile in Patients with Type 2 Diabetes Mellitus. Iran J Endocrinol Metab. 2016;15[6]:514–8.

Fanni G, Rosato R, Gentile L, Anselmino M, Frea S, Ponzo V, et al. Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study. J Transl Med [Internet]. 2020;18[1]:1–9. Available from: https://doi.org/10.1186/s12967-020-02357-1

Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95–104.

Jawad AH, Alsayed R, Emad M, Ibrahim AE, Al-Qaisi Z, Hairunisa N, Yousif E. Investigation of the Lipid Profile Level Fluctuation in Diabetes Mellitus Patients in Iraq. RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES. 2016 Nov 1;7]6[:1331-5].

Al-Naama L, Ajlan S, Mahmood M. The Medical Journal Basra University 2010; 28]1[: 28-32

Tang L, Tong Y, Zhang F, Chen G, Zhang YC, Jobin J, et al. The association of circulating irisin with metabolic risk factors in Chinese adults: A cross-sectional community-based study. BMC Endocr Disord. 2019;19[1]:1–6.

Balaban YA, Yilmaz N, Kalayci M, Unal M, Turhan T. Irisin and chemerin levels in patients with type 2 diabetes mellitus. Acta Endocrinol. 2019;15[4]:442.

Yano N, Zhao YT, Zhao TC. The Physiological Role of Irisin in the Regulation of Muscle Glucose Homeostasis. 2021;266–83.

Ökdemir D, Hatipoğlu N, Kurtoğlu S, Siraz ÜG, Akar HH, Muhtaroğlu S, et al. The role of irisin, insulin and leptin in maternal and fetal interaction. J Clin Res Pediatr Endocrinol. 2018;10(4):307.

Oguz A, Sahin M, Tuzun D, Kurutas EB, Ulgen C, Bozkus O, et al. Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus. 2021;0[May].

Shim YS, Kang MJ, Yang S, Hwang IT. Irisin is a biomarker for metabolic syndrome in prepubertal children. Endocr J. 2018;65[1]:23–31.

Akyuz A. Association Of Lower Serum Irisin Levels With Diabetes Mellitus: Irrespective Of Coronary Collateral Circulation, And SYNTAX Score. North Clin Istanbul. 2021;8[6]:607–14.

Oelmann S, Nauck M, Völzke H, Bahls M, Friedrich N. Circulating irisin concentrations are associated with a favourable lipid profile in the general population. PLoS One. 2016;11[4]:e0154319.

Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483.